ABL-MYC, a recombinant murine retrovirus that expresses v-abl and c-myc, rapidly induces transplantable mono-or oligoclonal plasmacytomas in BALB/c mice. To determine if the targets for trnsformation of this retrovirus are antigen-committed B lymphocytes and to explore this system as an alternative technique for producing antigenspecific monoclonal antibodies, plasmacytomas were induced in mice that had beep immunized with two different types of immunogens, hen egg white Iysozyme and sheep red blood cells.
Plasmacytomas typically arise with a mean lhtency of 240 days in up to 60%o of mice from susceptible strains (e.g., BALB/cAnPt) given an i.p. injection of mineral-oil (pristane) (1) . Pristane (tetramethylpentadecane)'leads to the development of oil granulomas in the mesenteries of the mice, and plasmacytomas arise in these tissues. The appearance of the tumors can be accelerated dramatically if Abelson murine leukemia virus (A-MuLV) 'is administered in addition to pristane (2) . Infection of pristane-primed mice with A-MuLV leads to the development of plasmacytomas in 10-30% of the mice between 60' and 120 days. Molecular genetic studies of plasmacytomas have revealed that 190%o of all plasmacytomas induced by i.p. injection of mineral oil, with or without A-MuLV, show a deregulation of the c-myr protooncogene due to chromosomal alterations (3, 4) . This universal deregulation of c-myc suggests that c-myc plays a major role in plasmacytomagenesis, although it appears to belonly one step in a multistep scenario. This multistep hypothesis was reinforced by the finding that plasma cell tumors were also generated rapidly by retroviral constructs created to study the cooperation of c-myc with different oncogenes. These oncogene combinations are Elw-c-myc (E. is the immunoglobulin heavy-chain enhancer) plus v-Ha-ras (5) and v-myc plus v-raf (6, 7) . Both combinations induced plasmacytomas, but only if mice were pristane-primed, and neither increased the tumor incidence above 60% in adult BALB/c mice.
Transgenic mice carrying Eg-v-abl develop plasmacytomas in concert with an activated c-myc gene, due to secondary chromosomal alterations. In addition, plasmacytomas occur rapidly in E-,v-abl x Ep-myc transgenic hybrid mice, without' pristane and in strains resistant to plasmacytoma induction with pristane alone (8) . Therefore we predicted that a retrovirus expressing these two oncogenes would rapidly and efficiently induce plasmacytomas. Thus ABL-MYC, a replicltion-defective retrovirus coexpressing v-abl and c-myc was constructed by inserting the protein-encoding portion of c-myc under the control of a herpes simplex thymidine kinase promoter into the A-MuLV backbone (9) . This virus rapidly induced plasmacytomas in 100o of adult BALB/c mice with or without helper virus and even in the absence of pristane (9, 10) . The average latency of tumor development was shorter than that observed with any other retroviral constructs.
Since dividing cells are particularly good targets for retroviral integration and transformation (11), we reasoned that antigen-stimulated B cells might be particularly good targets for ABL-MYC. Therefore, BALB/c mice were immunized twice with either hen egg white lysozyme (HEL) or sheep red blood cells (SRBC) before ABL-MYC infection with the intention of generating antigen-specific plasmacytomas. Immnunoassays. Automated particle-coupled fluorescence immunoassays (PCFIA), described by Jolley et al. (15) , were performed using a "screen machine" (Baxter/Pandex Division, Mundelein, IL). Polystyrene beads (0.9 um; Baxter/ Pandex) were coated with antigens either by direct absorption or by using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide coupling to carboxylated beads as described in detail by Rousseau et al. (16) . Coated beads were resuspended in PBS with 0.1% sodium azide. Antibody isotypes were determined on 1:104 dilutions of ascites fluid or serum samples from individual mice in an antigen-independent PCFIA as described (16 (17) .
MATERIALS AND METHODS
Association constants (K.) were calculated by using Scatchard plot analysis modified for ELISA as described (18, 19) and as modified for PCFIA by Lavoie et al. (17) .
In Vitro Culture of Plasmacytomas. 
Of 13 mice immunized with HEL and infected with ABL-MYC(M-MuLV), 11 produced antibodies strongly reactive with the antigen. These plasmacytomas continued to produce reactive antibodies following transplantation into unimmunized, pristane-primed mice. Plasmacytomas were considered positive if the ascites fluid of the transplant recipients showed reactivity (fluorescence intensity at least 3 times the background) with the antigen at dilutions of 1:104 or greater. The HEL-reactive antibodies secreted by the tumors included 4 IgAs, 5 IgMs, and 2 IgGs.
To evaluate the specificity of these antibodies, the ascites fluids were screened against a panel ofantigens developed for antibody repertoire studies (16) . Ascites samples reacting with two or more of these antigens were considered to be multireactive, with the exception of antibodies reacting with HEL and human lysozyme, which were considered to be specific for HEL and crossreacting with human lysozyme. As shown in Table 1 , six antibodies (one IgA, two IgG, and three IgM) showed reactivity with HEL alone, and five (two IgM and three IgA) reacted with at least two antigens and were classified as multireactive (16) . None of 12 tumors from unimmunized mice ( Table 1 , groups 3a and 3b) or of those specific for SRBC (Table 1, group 2) secreted antibodies specific for HEL.
The IgG antibodies of two of the ABL-MYC-induced plasmacytomas, AMHEL-8 and AMHEL-11, were purified as described above for more detailed characterization. Both AMHEL-8 and AMHEL-11 were monospecific with respect to the antigen-screening panel. Their binding to HEL was strong and HEL-inhibitable (Fig. 2) . The binding curves of AMHEL-8 and AMHEL-11 were compared to those of two hybridoma-derived IgG1 K monoclonal antibodies (HyHEL 12 and HyHEL 501) in Fig. 2 . Ka values for AMHEL-8 and AMHEL-11 were 2 x 109 and 1.3 x 109 liters/mol, respectively. These affinities are within the range (5 x 107-2 x 1010 liters/mol) of those determined by the same method for HEL-specific monoclonal antibodies generated by hybridoma technology (17, 27) .
To clone oligoclonal tumors to monoclonality, some of the plasmacytomas were adapted to growth in vitro in medium supplemented with 2000 units of IL-6 per mi. After a period of 1-2 months on an autologous feeder layer obtained from tumor nodules, the cells grew without a feeder layer, but remained strictly IL-6-dependent. After adaptation to in vitro culture, the ABL-MYC-induced plasmacytomas could be cloned by limiting dilution. The amount ofantibody produced by the in vitro cloned plasma cell lines was similar to that obtained from conventional hybridomas (1-10 ,ug/ml). AMHEL-2, one of the oligoclonal tumors cloned in vitro, secreted a monospecific IgM antibody and a multireactive IgA. After initial cloning in vitro, about two-thirds of the clones secreted only HEL-specific IgM antibodies. Some of these were cloned two more times by limiting dilution and then grown up for further analysis.
Southern blot analysis was performed to verify the clonality of the tumor and the lines in tissue culture. Fig. 3 shows a Southern blot of DNA isolated from the original tumor (AMH2 gO) and the first transplant generation (AMH2 gi) as well as from individual clones selected for production of the monospecific IgM antibody. Whereas with [355] methionine, and the total proteins in the supernatants were resolved by SDS/PAGE (Fig. 4A) . The major labeled proteins secreted were of appropriate size for the expected classes of immunoglobulin heavy (a = 55 kDa, 1L = 80 kDa, and y = 48 kDa) and light chains (23 kDa). The antibodies could be precipitated with HEL-coated polystyrene beads (Fig. 4B ), but did not show any cross-reactivity with BSA-coated polystyrene beads (Fig. 4C ). Binding to HEL beads was specific, since antibodies specific for antigens other than HEL did not bind to the HEL-coated beads (Fig. 4D) .
Similar experiments were performed with the particulate antigen SRBC. Immunized mice were infected with ABL-MYC in the presence or' absence of replication-competent helper virus (M-MuLV) to assess the effect of viral spread on antigen-specific tumor formation. ABL-MYC(qk2) can be used to generate plasmacytomas that will not produce additional ABL-MYC. Preventing the replication of ABL-MYC in vivo would limit the number of target cells that could become'infected in immunized animals. Thus the use of ABL-MYC(qk2) should allow us to more firmly distinguish target cell populations and to determine whether a cell is transformed before or after antigen commitment.
From 26 mice immunized with SRBC, 21 -were infected with ABL-MYC(qi2) ( Northern blot analysis of the plasmacytomas showed expression of both v-pbl and exogenous c-myc in the expected sizes. Probing of the blot with myc exon 1 revealed that the endogenous c-myc gene is barely expressed in these tumors (data not shown). From the seven HEL-specific tumors, two were monoclonal, three were biclonal, and two showed more than five rearrangements (data not shown). Data shown in Fig. 3 indicate that polyclonal tumors grow in vitro and can be cloned to monoclonality by limiting dilution.
DISCUSSION
Our results suggest that the major target for ABL-MYC transformation is. an antigen-committed B cell. Although B-cell clones that react specifically with a single antigen constitute a minor subset of the total B lymphocyte population, even after immunization, B cells reacting with the immunizing agent will be preferentially mitotically activated when a boost'immunization is administered (28 A comparison oflatencies in the presence (28 ± 7 days) or the absence (38 ± 7 days) of antigen shows differences (Fig. 1) . These findings support the theory of preferential expansion of antigen-committed B-cell pools and suggest that antigenic challenge accelerates the induction of plasmacytomas in this system by augmenting the pool of susceptible proliferating B cells.
More detailed analysis of two anti-HEL plasmacytomas established that antibodies obtained by ABL-MYC are comparable in affinity and specificity to those obtained by conventional techniques. Both were IgG1 K, the isotype found in more than 90% of anti-HEL hybridomas (16, 30) . This finding suggests that they originated from a similar anti-HEL B-cell pool as those obtained by conventional fusion techniques. Preliminary data obtained from fine-specificity analysis for HEL binding revealed that one of the IgGs showed a very rare fine specificity for HEL, suggesting that ABL-MYC can also target other B-cell pools. This notion is supported by the finding that several of the ABL-MYC tumors secreted HELspecific IgM and IgA antibodies, which are heavy-chain classes rarely found in BALB/c anti-HEL hybridomas (16, 30) . Similarly three of the antigen-specific anti-SRBC antibodies were IgA antibodies, suggesting that IgA antibodies are more likely to be obtained by using ABL-MYC transformation than by conventional spleen fusion techniques. Thus ABL-MYC produces a different spectrum of monoclonal antibodies than spleen fusions.
Since about 60% of the antigen-primed mice developed antigen-specific plasmacytomas, the use of this virus may prove to be a valuable alternative to the conventional hybridoma technique for production of monoclonal antibodies. When oligoclonal tumors arise, they can be cultured in vitro and cloned to monoclonality, as proven by Southern blot analysis in Fig. 3 . The plasmacytomas cultured in vitro secrete amounts of immunoglobulin comparable to those of splenic-derived hybridomas. To date, all ABL-MYC-induced plasmacytomas have been very stable in vivo and in vitro, and they can be readily transplanted into pristane-primed mice.
ABL-MYC offers another potential advantage over hybridomas for molecular genetic studies of immunoglobulin genes; namely, no fusions are required for immortalization ofcells and, therefore, no heterocaryons are produced by this technique.
ABL-MYC induces plasmacytomas in all mouse strains infected so far, even in those resistant to plasmacytoma induction by pristane alone (D.A.L., H.M., E.M.W., M. Potter, J.F.M., and R.R., unpublished results). Thus ABL-MYC is a very potent agent for mouse plasmacytomagenesis, and an amphotropic variant of this ecotropic virus might be useful for generating antigen-specific plasmacytomas in species other than mice, like rat, rabbit, or even man.
